Celdara Medical, LLC today announced that the National Cancer Institute (NCI) of the National Institutes of Health (NIH) has awarded a three-year Small Business Innovation Research (SBIR) Fast-Track award to fund the company’s advancement of CM-CX1, a chimeric antigen receptor (CAR) T cell therapy for the treatment of ovarian clear cell and renal cell carcinomas.
Dr. Jake Reder, Co-founder and Chief Executive Officer of Celdara Medical, remarked, “We are grateful to the NCI for their continued support of this program. The world has learned a lot about how to use CAR T therapies, and we’re now seeing successes against solid tumors as well as hematologic malignancies. Precise selection of target and indication was always part of this particular program, and we’re now keen to translate that potential into the clinic for the benefit of patients.”
“The clinical successes of CAR T cells against hematological malignancies have led us to the pursuit of CAR T therapies against multiple targets for the treatment of solid tumors,” Dr. Joana Murad Mabaera, Executive Director of Research at Celdara Medical and lead Principal Investigator on this study noted. “I have been working closely with our industry and academic partners to identify ideal targets for cellular therapies and we have created something unique with CM-CX1. The funding by the National Cancer Institute (NCI) provides us with an exciting opportunity to translate our promising research and make this therapeutic option accessible to patients.”
Research reported in this press release is supported by the National Cancer Institute of the National Institutes of Health under award number R44CA265424. The content is solely the responsibility of Celdara Medical and does not necessarily represent the official views of the National Institutes of Health.
About Celdara Medical, LLC
Celdara Medical was founded by Drs. Jake Reder and Michael Fanger in 2008, and is headquartered at the Dartmouth Regional Technology Center (DRTC) in Lebanon, NH. Celdara Medical builds academic and early-stage innovations into high-potential medical companies, identifying discoveries of exceptional value at the earliest stages and moving them toward the market. Celdara Medical partners with inventors and their institutions, providing the developmental, financial, and business acumen required to bridge discovery and profitability. With robust funding options, a diverse and high impact Programmatic pipeline, and partnerships with world-class academic institutions and industry leaders, Celdara Medical navigates all aspects of a complex industry, accelerating science to improve human health. Further information about Celdara Medical is available at